CJ Bioscience
Financials
Valuation Metrics
CJ Bioscience's Market Cap is ₩481B. At end of 2025 it was ₩1218B. Ranked #1793 of 2,421 in KR market (top 74%), #1097 of 1,640 on KOSDAQ (top 67%), #73 of 96 in Health Care Equipment & Services (top 76%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 48.08B KRW | KR#1,793/2,421 Sec#73/96 |
| Revenue | 3.68B KRW | KR#2,356/2,421 Sec#91/96 |
| Net Income | -22.33B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 60.39B KRW | KR#2,102/2,421 Sec#68/96 |
| Net Assets | 41.75B KRW | KR#2,023/2,421 Sec#69/96 |
| Employees | 129 | KR#1,446/2,421 Sec#51/96 |
| Value | ||
| P/B | 1.15x | KR#1,584/2,421 Sec#49/96 |
| P/S | 13.08x | KR#2,302/2,421 Sec#88/96 |
| FCF Yield | -48.72% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | -53.48% | KR#2,286/2,421 Sec#86/96 |
| ROA | -36.97% | KR#2,341/2,421 Sec#89/96 |
| Op. Margin | -624.86% | KR#2,373/2,421 Sec#95/96 |
| Revenue Growth | 8.72% | KR#970/2,421 Sec#52/96 |
| Financial Health | ||
| Debt Ratio | 44.66% | KR#883/2,421 Sec#49/96 |
| Total Debt | 7.88B KRW | KR#1,693/2,421 Sec#53/96 |
| FCF | -23.43B KRW | KR#1,931/2,421 Sec#75/96 |
| Cash | 4.56B KRW | KR#2,032/2,421 Sec#74/96 |
| Current Ratio | 2.88x | KR#590/2,421 Sec#35/96 |
| Performance | ||
| 1Y Return | -63.53% | KR#2,246/2,421 Sec#87/96 |
| 1M Return | -3.03% | KR#1,589/2,421 Sec#52/96 |
| From 52W High | -64.72% | KR#2,024/2,421 Sec#72/96 |
| 1Y MDD | -68.81% | KR#1,942/2,421 Sec#69/96 |
| Trading | ||
| Volume | 4,325 shares | KR#2,154/2,421 Sec#87/96 |
| Trading Value | 15.9M KRW | KR#2,193/2,421 Sec#85/96 |
| Foreign Own. | 2.77% | KR#1,367/2,421 Sec#47/96 |
| Per Share | ||
| EPS | -1,709 KRW | KR—/2,421 Sec—/96 |
| BPS | 3,195 KRW | KR#1,817/2,421 Sec#55/96 |
Company Info
CJ Bioscience, a microbiome specialized company, was established in 2009 and listed on the KOSDAQ market in 2019. The company engages in therapeutic new drug development via its Artificial Intelligence-based microbiome big data platform, bioinformatics analysis services, and customized healthcare solutions. It offers new drug candidate material analysis based on the Ez-Mx® platform, microbial genome analysis utilizing EzBioCloud and N integrated solutions, and customized healthcare services leveraging a human microbiome database of over 140,000 cases. CJ Bioscience is headquartered in Jung-gu, Seoul.